Lupin Appoints Alok Sonig As CEO – US Generics And Global Head – Generics R&D & Biosimilars

Pharma major Lupin Limited announced the appointment of Alok Sonig as CEO – US Generics and Global Head – Generics R&D & Biosimilars. Alok will lead and have overall responsibility for the US Generics business including Research & Development in India and the US and the Commercial side of the business in the US. He will also be responsible for Lupin’s global Biosimilars business.

With over 23 years of experience in the industry, Alok brings an established track record of success in the Pharmaceutical and Healthcare sectors to Lupin. Most recently, Alok was CEO of Developed Markets (US, Canada, Europe and Japan) at Dr. Reddy's. He joined Dr. Reddy’s in 2012 and ran their India business till 2015 before moving back to the US to run their North America business. Prior to Dr. Reddy’s, Alok spent nearly 15 years at Bristol-Myers Squibb, where he held several positions of increasing responsibilities in General Management, Country leadership roles, Global Strategy and Marketing. Alok holds a Bachelor’s of Engineering from Punjab Engineering College in India, and an MBA from American University, Washington, D.C.

Commenting on the appointment, Ms. Vinita Gupta, Chief Executive Officer, and Mr. Nilesh Gupta, Managing Director, Lupin said, “We are delighted to welcome Alok to Lupin. His global experience, strategic perspective, and operational focus will help accelerate our team’s efforts to strengthen and evolve our US generics business as we execute on near-term growth opportunities and navigate new platforms in complex generics and biosimilars.”

Alok will be based out of Somerset, New Jersey and split his time between Lupin’s Somerset, Baltimore and India offices. He will report to Ms. Vinita Gupta – Chief Executive Officer, Lupin and Mr. Nilesh Gupta – Managing Director, Lupin.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6 th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. For more information, visit http://www.lupin.com.